FINWIRES · TerminalLIVE
FINWIRES

Sichuan Biokin Pharma Posts 128% Profit Drop in 2025 as Revenue Halves; Shares Down 3%

By

-- Sichuan Biokin Pharmaceutical (SHA:688506) reported a 128% decrease in net profit in 2025 to 1.05 billion yuan from 3.71 billion yuan a year earlier.

Earnings per share plunged to 2.61 yuan from 9.25 yuan, the pharmaceutical company said in a Shanghai bourse filing on Tuesday.

Revenue slumped 57% to 2.52 billion yuan from 5.82 billion yuan.

Biokin attributed the lackluster performance to a high comparison base as the revenue generated in 2024 benefited from the intellectual property cooperation agreement it reached with BMS on a product called Iza-bren.

Shares of the company fell 3% in recent trade.

Related Articles

Asia

Syntara Receives Positive US FDA Feedback for Clinical Trial of Bone Marrow Cancer Treatment

Syntara (ASX:SNT) received positive feedback from the US Food and Drug Administration following a type C meeting, supporting the design of its planned phase 2b clinical trial of amsulostat for the treatment of myelofibrosis, according to a Tuesday filing with the Australian bourse.The primary endpoint of the phase 2b study will be the achievement of a 50% reduction in the total symptom score following nine months of treatment, with about 100 patients expected to be enrolled, per the filing.The positive feedback from the US FDA allows for amsulostat's progression into late-stage clinical development and paves the way for further engagement with prospective commercial partners, the company said.Myelofibrosis is a type of bone marrow cancer where the accumulation of scar tissue leads to a loss of red and white blood cells and platelets.

$ASX:SNT
Asia

Market Chatter: Japan IPO Market Will Stay Subdued as AI Stocks Draw Investors

Japan's IPO market will remain under pressure despite strong debuts from a sake brewer and a pet food maker, as investors continue to favor AI-related stocks, Reuters reported Tuesday.Shares of Umenoyado Brewery (TYO:559A) rose about 75% on their first trading day, while Inuneko-Seikatsu (TYO:556A) gained more than 30% after listing. The gains contrast with broader weakness, with many new listings trading below their offer prices this year, the report said.Investor focus on AI leaders such as SoftBank Group (TYO:9984) and Advantest (TYO:6857) has diverted flows away from smaller, domestically focused IPO candidates. Stricter listing standards from the Tokyo Stock Exchange are also weighing on activity, with companies facing tougher valuation thresholds in coming years, according to the report.The number of IPOs in Tokyo will likely fall about 20% this year from 2025 levels, as retail investors prioritize short-term gains in large-cap technology stocks over new listings, the report said.(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)

$^N225$TYO:556A$TYO:559A$TYO:6857$TYO:9984
Asia

Magma Group Completes Private Placement of Shares

Magma Group (KLSE:MAGMA) completed the listing and quotation of 18.9 million shares on the Main Market of Bursa Securities, according to a Monday Malaysian bourse filing.Shares dropped about 2% in Tuesday's recent trade.The company had proposed a private placement of up to 10% of its total shares to third-party investors.

$KLSE:MAGMA